Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

05-12-2014 | Hematologic cancers | Book chapter | Article

23. Quality of Life in Hodgkin Lymphoma

Authors: Teresa V. Halbsguth, Hans-Henning Flechtner

Publisher: Springer International Publishing

Login to get access

Abstract

The long-term cure rates for Hodgkin lymphoma (HL) patients are above 80 % for all stages. Given this impressive long-term outcome for a patient population with a median age of about 30 years at diagnosis, the quality of survivorship has become more and more important. Organ dysfunctions including hypothyroidism, hypogonadism, cardiopulmonary complications, and secondary neoplasia as well as health-related quality of life (HRQoL) are major factors contributing to the patient’s general well-being.
Literature
1.
Ganz PA, Moinpour CM, Pauler DK et al (2003) Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest oncology group study 9133. J Clin Oncol 21:3512–3519PubMedCrossRef
2.
Heutte N, Flechtner HH, Mounier N et al (2009) Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 10:1160–1170PubMedCrossRef
3.
U.S. Department of Health and Human Services Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims
4.
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
5.
Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
6.
Flechtner H, Ruffer JU, Henry-Amar M et al (1998) Quality of life assessment in Hodgkin’s disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC lymphoma cooperative group. Groupe D’Etude des Lymphomes de L’Adulte and German Hodgkin Study Group. Ann Oncol 9(Suppl 5):S147–S154PubMedCrossRef
7.
Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371–383PubMedCrossRef
8.
Bottomley A, Flechtner H, Efficace F et al (2005) Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 41:1697–1709PubMedCrossRef
9.
Cremeens J, Eiser C, Blades M (2006) Characteristics of health-related self-report measures for children aged three to eight years: a review of the literature. Qual Life Res 15:739–754PubMedCrossRef
10.
Calaminus G, Doerffel W, Baust K, Teske C, Riepenhausen M, Brämswig J, Flechtner HH, Singer S, Hinz A, Schellong G (2014) Quality of life in long-term survivors following treatment for Hodgkin’s disease during childhood and adolescence in the German multicentre studies between 1978 and 2002. Support Care Cancer 22:1519–1529PubMedCrossRef
11.
Roper K, McDermott K, Cooley ME, Daley K, Fawcett J (2009) Health-related quality of life in adults with Hodgkin’s disease: the state of the science. Cancer Nurs 32:E1–E17; quiz E18–E19PubMedCrossRef
12.
Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D (1986) Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 4:805–814PubMed
13.
Joly F, Henry-Amar M, Arveux P et al (1996) Late psychosocial sequelae in Hodgkin’s disease survivors: a French population-based case-control study. J Clin Oncol 14:2444–2453PubMed
14.
Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S (1999) Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 17:253–261PubMed
15.
Wettergren L, Bjorkholm M, Axdorph U, Bowling A, Langius-Eklof A (2003) Individual quality of life in long-term survivors of Hodgkin’s lymphoma – a comparative study. Qual Life Res 12:545–554PubMedCrossRef
16.
Wettergren L, Bjorkholm M, Axdorph U, Langius-Eklof A (2004) Determinants of health-related quality of life in long-term survivors of Hodgkin’s lymphoma. Qual Life Res 13:1369–1379PubMedCrossRef
17.
Wettergren L, Bjorkholm M, Langius-Eklof A (2005) Validation of an extended version of the SEIQoL-DW in a cohort of Hodgkin lymphoma survivors. Qual Life Res 14:2329–2333PubMedCrossRef
18.
Ruffer JU, Flechtner H, Tralls P et al (2003) Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39:2179–2186PubMedCrossRef
19.
Holzner B, Kemmler G, Cella D et al (2004) Normative data for functional assessment of cancer therapy – general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43:153–160PubMedCrossRef
20.
Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH (2006) Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer 42:327–333PubMedCrossRef
21.
Borchmann P, Muller H, Brillant C et al (2010) Longitudinal evaluation of quality of life and fatigue in Hodgkin lymphoma patients. ASH Ann Meet Abstr 116:935
22.
Behringer K, Muller H, Gorgen H et al (2013) Sexual quality of life in Hodgkin lymphoma: a longitudinal analysis by the German Hodgkin Study Group. Br J Cancer 108:49–57PubMedCentralPubMed
Image Credits